Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

USFDA action on Indoco Plants: Angel Broking

Posted On: 2017-04-04 21:01:03

Views of Ms. Sarabjit Kour Nangra (VP Research- Pharma, Angel Broking):

"The USFDA had inspected Indoco Remedies manufacturing facilities (Plant II & Plant III, L-32,33,34 Verna Industrial Estate Area, Verna, Goa), from August 31st 2016 to September 4th, 2016.As an outcome of this inspection, the facility received 6 observations in Form 483, which do not pertain to data integrity. Based on the review of compliance response, USFDA accepted company's response to 4 observations. However, FDA remains concerned with respect to 2 observations, pertaining to one specific product, for which the company is contract manufacturer, for one of its customers and consequently, the company has received a warning letter from USFDA dated 27th March 2017. The company is fully committed in resolving the issue and will respond at the earliest.

As per the company, warning letter pertains to issue of leakages in the product Latanoprost, which has sales of INR 25cr p.a. Revenue exposure of plant under warning to U.S. is INR 75cr, out of the total U.S. business of INR 110cr. In terms of number of ANDAs pending from Plant III is 9, while number of ANDAs pending from Plant II is 18. While the company does not expect disruptions in supplies as of now, it expects the delay in approvals in future. AS of now the damage is very minimal to the US operations of the company and even in the worst come situation (if all the INR 75cr sales are under pressure), the impact on the net profit is expected to around 6-7%. We maintain our NEUTRAL rating on the stock."

Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.228.95 as compared to the previous close of Rs. 249.95. The total number of shares traded during the day was 226701 in over 7647 trades.

The stock hit an intraday high of Rs. 234 and intraday low of 209. The net turnover during the day was Rs. 49993818.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Bajaj Auto - 1QFY2018 Result Update - Angel Broking
Persistent Systems - Q1FY18 Result Update Rating - NEUTRAL - Arihant Capital Markets Ltd
HDFC Bank Q1FY18 Results- Core performance continues to be robust: Angel Broking
Result Update: MRPL - ACCUMULATE - TP Rs.138 - Kotak
Result Update: Zensar Technologies Ltd - REDUCE - TP Rs.839 - Kotak
Result Update: NIIT Technologies Ltd - ACCUMULATE - TP Rs.550 - Kotak
Strategy: A not-so 'trump-ant' rally - Kotak
Bajaj Auto - Q1FY18 Result Update Rating - NEUTRAL - Arihant Capital Markets Limited
KPIT - Q1FY18 Result Update Rating - Reduce - Arihant capital Markets Ltd
RIL narrative shifts to Jio: Angel Broking
An autumn taper discussion provides fodder to Euro bulls: Angel Commodities Broking
Rhythm of profitable investment - Music Broadcast Limited - Initiating Coverage: Angel Broking
India: Monsoon Tracker: Normal again - Kotak
Views on Wipro Limited 1QFY2018 Results: Angel Broking
Ultratech Cement Ltd Q1FY18 Result Update Rating - HOLD - Arihant capital Markets Ltd
Views on Alembic Pharmaceuticals - 1QFY2018 Results: Angel Broking
Sanofi India Q2CY17 Result Update Rating - HOLD - Arihant Capital Markets Limited
Bajaj Auto - Q1FY18 Earnings First Cut - Arihant Capital Markets Limited
Higher raw material costs impact Bajaj Auto's Q1 Result: Angel Broking
Strategy: Weak 1QFY18 direct tax revenues suggest growth pangs - Kotak
ACC Ltd - Q2CY17 Result Update Rating - HOLD - Arihant Capital Markets
Tata Consultancy Services Limited - 1QFY2018 Result Update - Angel Broking
Result Update: Hindustan Unilever Ltd - Kotak
Infosys Ltd - 1QFY2018 Result Update - Angel Broking
Cigarette makers under fire over increased Cess: Angel Broking
GST, BSIV transition impacts Ashok Leyland's profitability: Angel Broking
Result Update: KPIT Technologies Ltd - SELL - TP Rs.121 - Kotak
Result Update: Hindustan Zinc Ltd - REDUCE - TP Rs.285 - Kotak
Result Update: Kansai Nerolac Paints Ltd - BUY - TP Rs.515 - Kotak
Company Update: Gujarat State Petronet Ltd - ACCUMULATE - TP Rs.182 - Kotak
Company Update: Allcargo Logistics Ltd. - BUY - TP Rs.205 - Kotak
Banks : Where is capital consumption in public banks? : Deep dive into capital consumption and requirements - Kotak
The Pitch Report - Result Update: Karnataka Bank Ltd - BUY - TP Rs.220 - Kotak
Chhota (to) MOTA ideas: Venky's (india) Ltd - REDUCE - TP Rs.2200 - Kotak
Bajaj Corp - GST impacts reported results; Retail growth encouraging though - JM Financial
Hatsun Agro Ltd - Result Update - Q1FY18 - KR Choksey
Views on Infosys Limited 1QFY2018 Results: Angel Broking
The Pitch Report: Sutlej Textiles - BUY - TP Rs.1220 - Kotak
Result Update : Cyient Ltd (Cyient) - REDUCE - TP Rs.521 - Kotak
Company Visit Note : Shankara Building Products Ltd - Kotak
Views on Tata Consultancy Services Limited 1QFY2018 Results: Angel Broking
Economy: Inflation comfort to prompt a rate cut - Kotak
Petroleum consumption grows 0.4% in June after growing 3-5% in April and May
Energy-petroleum consumption: Slow and unsteady - Kotak
Metals & Mining (Attractive): 1QFY18-a tad weak due to lower prices, one-offs - Kotak
HPCL may finally become an arm of upstream ONGC: Angel Broking
Economy: FX outlook: No radical turning of tide - Kotak
Company Visit Note: Rajoo Engineers Ltd (REL) - NOT RATED - Kotak
Infrastructure: LPG - at the forefront of growth - Kotak
Banks : Marginal improvement - Annual report analysis on NPLs, restructured loans and others - Kotak


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017